1399584-78-1
1399584-78-1
Chemical Structure
Romilkimab
Synonym(s): SAR156597
- CAS No.: 1399584-78-1
- Formula:N/A
- Molecular Weight:(197.9 kDa)
SMILES: [Romilkimab]
Biological Activity: Romilkimab (SAR156597) is a humanized IG antibody that specifically targets IL-4 and IL-13. Romilkimab can be used for the research of diffuse cutaneous systemic sclerosis[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Romilkimab | 99.01% | Romilkimab (SAR156597) is a humanized IG antibody that specifically targets IL-4 and IL-13. Romilkimab can be used for the research of diffuse cutaneous systemic sclerosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Fernández-Lázaro D, et al. Impact of Innovative Treatment Using Biological Drugs for the Modulation of Diffuse Cutaneous Systemic Sclerosis: A Systematic Review. Medicina (Kaunas). 2023 Jan 27;59(2):247. [Content Brief]
- [2]. Allanore Y, et al. A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2020;79(12):1600-1607. [Content Brief]
- [3]. Raghu G, et al. SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772). Eur Respir J. 2018;52(6):1801130. Published 2018 Dec 13. [Content Brief]
